These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 34526099)
1. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. Zhang XH; Chen J; Han MZ; Huang H; Jiang EL; Jiang M; Lai YR; Liu DH; Liu QF; Liu T; Ren HY; Song YP; Sun ZM; Tang XW; Wang JM; Wu DP; Xu LP; Zhang X; Zhou DB; Huang XJ J Hematol Oncol; 2021 Sep; 14(1):145. PubMed ID: 34526099 [TBL] [Abstract][Full Text] [Related]
2. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. Xu L; Chen H; Chen J; Han M; Huang H; Lai Y; Liu D; Liu Q; Liu T; Jiang M; Ren H; Song Y; Sun Z; Wang J; Wu D; Zhou D; Zou P; Liu K; Huang X J Hematol Oncol; 2018 Mar; 11(1):33. PubMed ID: 29495966 [TBL] [Abstract][Full Text] [Related]
3. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713 [TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
7. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062 [TBL] [Abstract][Full Text] [Related]
8. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361 [TBL] [Abstract][Full Text] [Related]
9. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. Huang X; Liu D Clin Transpl; 2011; ():237-45. PubMed ID: 22755417 [TBL] [Abstract][Full Text] [Related]
10. Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Gao L; Yang L; Zhou S; Zhu W; Han Y; Chen S; Xue S; Wang Y; Qiu H; Wu D; Wu X Stem Cell Res Ther; 2024 Jan; 15(1):24. PubMed ID: 38282037 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation. Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386 [TBL] [Abstract][Full Text] [Related]
12. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant]. Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201 [No Abstract] [Full Text] [Related]
13. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. Czyz A; Nagler A Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875 [TBL] [Abstract][Full Text] [Related]
14. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612 [TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. Merli P; Algeri M; Del Bufalo F; Locatelli F Curr Hematol Malig Rep; 2019 Apr; 14(2):94-105. PubMed ID: 30806963 [TBL] [Abstract][Full Text] [Related]
16. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia. Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575 [TBL] [Abstract][Full Text] [Related]
17. Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation. Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Kudo S; Ikeda K; Ohto H; Kikuta A Int J Hematol; 2022 Mar; 115(3):414-423. PubMed ID: 34822127 [TBL] [Abstract][Full Text] [Related]
18. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Yanir AD; Martinez CA; Sasa G; Leung K; Gottschalk S; Omer B; Ahmed N; Hegde M; Eunji J; Liu H; Heslop HE; Brenner MK; Krance RA; Naik S Biol Blood Marrow Transplant; 2018 Jul; 24(7):1424-1431. PubMed ID: 29550628 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia. Ciftciler R; Demiroglu H; Buyukasık Y; Aladag E; Aksu S; Haznedaroglu IC; Sayınalp N; Ozcebe O; Malkan UY; Goker H Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):177-182. PubMed ID: 30616990 [TBL] [Abstract][Full Text] [Related]
20. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]